{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:15:21Z","timestamp":1771006521899,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T00:00:00Z","timestamp":1240358400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1741-7015-7-19","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T18:13:51Z","timestamp":1240424031000},"source":"Crossref","is-referenced-by-count":60,"title":["Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis"],"prefix":"10.1186","volume":"7","author":[{"given":"Hendrik Simon","family":"Schaaf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karien","family":"Cilliers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetre","family":"Labadarios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes Stephanus","family":"Maritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory D","family":"Hussey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Roderick","family":"Donald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,4,22]]},"reference":[{"key":"197_CR1","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1378\/chest.113.5.1178","volume":"113","author":"ME Kimmerling","year":"1998","unstructured":"Kimmerling ME, Phillips P, Patterson P, Hall MH, Robinson CA, Dunlap NE: Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest. 1998, 113: 1178-1183. 10.1378\/chest.113.5.1178.","journal-title":"Chest"},{"key":"197_CR2","first-page":"972","volume":"11","author":"S-W Um","year":"2007","unstructured":"Um S-W, Lee SW, Kwon SY, Yoon HI, Park KU, Song J, Lee C-T, Lee J-H: Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis. 2007, 11: 972-978.","journal-title":"Int J Tuberc Lung Dis"},{"key":"197_CR3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/106002809603000901","volume":"30","author":"CA Peloquin","year":"1996","unstructured":"Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME, Berning SE, Gerena GT: Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother. 1996, 30: 919-925.","journal-title":"Ann Pharmacother"},{"key":"197_CR4","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1128\/AAC.48.11.4473-4475.2004","volume":"48","author":"P Gurumurthy","year":"2004","unstructured":"Gurumurthy P, Ramachandran G, Kumar AKH, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, Bhagavathy S, Venkatesan P, Sekar L, Mahilmaran N, Paramesh P: Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother. 2004, 48: 4473-4475. 10.1128\/AAC.48.11.4473-4475.2004.","journal-title":"Antimicrob Agents Chemother"},{"key":"197_CR5","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1086\/498024","volume":"41","author":"DC Perlman","year":"2005","unstructured":"Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Remmel RP, Salomon N, Hafner R, Peloquin CA: The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis. 2005, 41: 1638-1647. 10.1086\/498024.","journal-title":"Clin Infect Dis"},{"key":"197_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1086\/514513","volume":"25","author":"SH Choudhri","year":"1997","unstructured":"Choudhri SH, Hawken M, Gathua S, Minyiri GO, Watkins W, Sahai J, Sitar DS, Aoki FY, Long R: Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS and diarrhea. Clin Infect Dis. 1997, 25: 104-111. 10.1086\/514513.","journal-title":"Clin Infect Dis"},{"key":"197_CR7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5588\/09640569513002","volume":"6","author":"R van Crevel","year":"2002","unstructured":"van Crevel R, Alisjahbana B, de Lange WCM, Borst F, Danusantoso H, Meer JWM, van der, Burger D, Nelwan RHH: Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis. 2002, 6: 497-502.","journal-title":"Int J Tuberc Lung Dis"},{"key":"197_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1086\/431984","volume":"41","author":"JW Tappero","year":"2005","unstructured":"Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, Oyewo A, Talbot EA, Kenyon TA, Moeti TL, Moffat HJ, Peloquin CA: Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis. 2005, 41: 461-469. 10.1086\/431984.","journal-title":"Clin Infect Dis"},{"key":"197_CR9","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1128\/AAC.50.4.1170-1177.2006","volume":"50","author":"H McIlleron","year":"2006","unstructured":"McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P: Determinants of rifampin, isoniazid, pyrazinamide and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother. 2006, 50: 1170-1177. 10.1128\/AAC.50.4.1170-1177.2006.","journal-title":"Antimicrob Agents Chemother"},{"key":"197_CR10","first-page":"670","volume":"2","author":"B Taylor","year":"1998","unstructured":"Taylor B, Smith PJ: Does AIDS impair the absorption of antituberculosis agents?. Int J Tuberc Lung Dis. 1998, 2: 670-675.","journal-title":"Int J Tuberc Lung Dis"},{"key":"197_CR11","first-page":"25","volume":"81","author":"S Jaruratanasirikul","year":"1998","unstructured":"Jaruratanasirikul S: The pharmacokinetics of rifampicin in AIDS patients. J Med Assoc Thai. 1998, 81: 25-28.","journal-title":"J Med Assoc Thai"},{"key":"197_CR12","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/jac\/dkm393","volume":"60","author":"H McIlleron","year":"2007","unstructured":"McIlleron H, Norman J, Kanyok TP, Fourie PB, Horton J, Smith PJ: Elevated gatifloxicin and reduced rifampicin concentration in a single-dose interaction study amongst healthy volunteers. J Antimicrob Chemother. 2007, 60: 1398-1401. 10.1093\/jac\/dkm393.","journal-title":"J Antimicrob Chemother"},{"key":"197_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0899-9007(97)00226-8","volume":"14","author":"MR Mascarenas","year":"1998","unstructured":"Mascarenas MR, Zemel B, Stallings VA: Nuritional assessment in pediatrics. Nutrition. 1998, 14: 105-115. 10.1016\/S0899-9007(97)00226-8.","journal-title":"Nutrition"},{"key":"197_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1146\/annurev.nutr.17.1.211","volume":"17","author":"BS Zemel","year":"1997","unstructured":"Zemel BS, Riley EM, Stallings VA: Evaluation of methodology for nutritional assessment in children: anthropometry, body composition, and energy expenditure. Annu Rev Nutr. 1997, 17: 211-235. 10.1146\/annurev.nutr.17.1.211.","journal-title":"Annu Rev Nutr"},{"key":"197_CR15","first-page":"119","volume":"32","author":"MB Pepys","year":"1978","unstructured":"Pepys MB, Dash AC, Markham RE, Thomas HC, Williams BD, Petrie A: Comparative clinical study of protein SAP (amyloid A component) and C-reactive protein in serum. Clin Exp Immunol. 1978, 32: 119-124.","journal-title":"Clin Exp Immunol"},{"key":"197_CR16","first-page":"31","volume":"22","author":"CA Peloquin","year":"1992","unstructured":"Peloquin CA: Therapeutic drug monitoring: principles and applications in mycobacterial infections. Drug Ther. 1992, 22: 31-36.","journal-title":"Drug Ther"},{"key":"197_CR17","volume-title":"The Pharmacokinetics of Rimactane in Children. Symposium on Rimactane","author":"B Krauer","year":"1968","unstructured":"Krauer B: The Pharmacokinetics of Rimactane in Children. Symposium on Rimactane. 1968, Basel: Dettli L, 5."},{"key":"197_CR18","first-page":"755","volume-title":"Proceedings of the Sixth International Congress of Chemotherapy 1969; Tokyo","author":"G Acocella","year":"1970","unstructured":"Acocella G, Buniva G, Flauto U, Nicolis FB: Absorption and elimination of the antibiotic rifampicin in newborns and children. Proceedings of the Sixth International Congress of Chemotherapy 1969; Tokyo. 1970, Tokyo: University of Tokyo Press, 2: 755-760."},{"key":"197_CR19","first-page":"191","volume":"21","author":"N Bergamini","year":"1970","unstructured":"Bergamini N, Matnardi L, Rosaschino F: Tassi ematici eliminazione urinaria di Rifampicina nei lattanti. Aggiorn Pediatr. 1970, 21: 191-197.","journal-title":"Aggiorn Pediatr"},{"key":"197_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF02179950","volume":"149","author":"H Hussels","year":"1973","unstructured":"Hussels H, Kroening U, Magdorf K: Ethambutol and rifampicin serum levels in children: second report on the combined administration of ethambutol and rifampicin. Pneumonologie. 1973, 149: 31-38. 10.1007\/BF02179950.","journal-title":"Pneumonologie"},{"key":"197_CR21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1542\/peds.66.1.17","volume":"66","author":"GH McCracken","year":"1980","unstructured":"McCracken GH, Ginsburg CM, Zweighaft TC, Clahsen J: Pharmacokinetics of rifampin in infants and children: relevance to prophylaxis against Haemophilus influenzae type B disease. Pediatrics. 1980, 66: 17-21.","journal-title":"Pediatrics"},{"key":"197_CR22","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1128\/AAC.37.11.2401","volume":"37","author":"TQ Tan","year":"1993","unstructured":"Tan TQ, Mason EO, Ou C-N, Kaplan SL: Use of intravenous rifampin in neonates with persistent staphylococcal bacteraemia. Antimicrob Agents Chemother. 1993, 37: 2401-2406.","journal-title":"Antimicrob Agents Chemother"},{"key":"197_CR23","first-page":"1341","volume":"29","author":"V Seth","year":"1992","unstructured":"Seth V, Beotra A, Bagga A, Seth S: Drug therapy in malnutrition. Indian Pediatr. 1992, 29: 1341-1346.","journal-title":"Indian Pediatr"},{"key":"197_CR24","first-page":"1091","volume":"30","author":"V Seth","year":"1993","unstructured":"Seth V, Beotra A, Seth SD, Semwal OP, Kabra S, Jain Y, Mukhopadhya S: Serum concentrations of rifampicin and isoniazid in tuberculosis. Indian Pediatr. 1993, 30: 1091-1098.","journal-title":"Indian Pediatr"},{"key":"197_CR25","first-page":"269","volume":"29","author":"M Mahajan","year":"1997","unstructured":"Mahajan M, Rohatgi D, Talwar V, Patni SK, Mahajan P, Agarwal DS: Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis. J Commun Dis. 1997, 29: 269-274.","journal-title":"J Commun Dis"},{"key":"197_CR26","volume-title":"Guidelines for National Programmes","author":"World Health Organization","year":"2003","unstructured":"World Health Organization: Treatment of tuberculosis. Guidelines for National Programmes. 2003, WHO\/CDS\/TB\/2003.313. Geneva"},{"key":"197_CR27","volume-title":"Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children","author":"World Health Organization","year":"2006","unstructured":"World Health Organization: Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. 2006, WHO\/HTM\/TB\/2006.371. Geneva"},{"key":"197_CR28","first-page":"63","volume-title":"Pharmaceutical Calculations","author":"HC Ansel","year":"2001","unstructured":"Ansel HC, Stoklosa MJ: Calculation of doses. Pharmaceutical Calculations. 2001, Philadelphia, PA: Lippincott Williams & Wilkins, 63-91."},{"key":"197_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/01.inf.0000195619.76277.3f","volume":"25","author":"PJ Weidle","year":"2006","unstructured":"Weidle PJ, Abrams EJ, Gvetadze R, Rivadeneira E, Kline MW: A simplified weight-based method for pediatric drug dosing for zidovudine and didanosine in resource-limited settings. Pediatr Infect Dis J. 2006, 25: 59-64. 10.1097\/01.inf.0000195619.76277.3f.","journal-title":"Pediatr Infect Dis J"},{"key":"197_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1164\/rccm.167.4.603","volume":"167","author":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America","year":"2003","unstructured":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med. 2003, 167: 603-662. 10.1164\/rccm.167.4.603.","journal-title":"Am J Respir Crit Care Med"},{"key":"197_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.tube.2007.08.002","volume":"87","author":"H McIlleron","year":"2007","unstructured":"McIlleron H, Watkins ML, Folb PI, Ress SR, Wilkinson RJ: Rifampin levels, interferon-gamma release and outcome in complicated pulmonary tuberculosis. Tuberculosis (Edinb). 2007, 87: 557-564. 10.1016\/j.tube.2007.08.002.","journal-title":"Tuberculosis (Edinb)"},{"key":"197_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10096-007-0454-6","volume":"27","author":"KC Chang","year":"2008","unstructured":"Chang KC, Leung CC, Yew WW, Kam KM, Yip CW, Ma CH, Tam CM, Leung EC, Law WS, Leung WM: Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur J Clin Microbiol Infect Dis. 2008, 27: 467-472. 10.1007\/s10096-007-0454-6.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"197_CR33","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1164\/rccm.200407-905OC","volume":"170","author":"KC Chang","year":"2004","unstructured":"Chang KC, Leung CC, Yew WW, Ho SC, Tam CM: A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med. 2004, 170: 1124-1130. 10.1164\/rccm.200407-905OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"197_CR34","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1164\/rccm.200605-637OC","volume":"174","author":"KC Chang","year":"2006","unstructured":"Chang KC, Leung CC, Yew WW, Chan SL, Tam CM: Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006, 174: 1153-1158. 10.1164\/rccm.200605-637OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"197_CR35","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1164\/rccm.200509-1529OC","volume":"175","author":"P Nahid","year":"2007","unstructured":"Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Masae Kawamura L, Osmond DH, Hopewell PC, Daley CL: Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med. 2007, 175: 1199-1206. 10.1164\/rccm.200509-1529OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"197_CR36","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1056\/NEJM199503233321204","volume":"332","author":"JH Perri\u00ebns","year":"1995","unstructured":"Perri\u00ebns JH, St Louis ME, Mukadi YB: Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Eng J Med. 1995, 332: 779-784. 10.1056\/NEJM199503233321204.","journal-title":"N Eng J Med"},{"key":"197_CR37","first-page":"879","volume":"119","author":"MW Long","year":"1979","unstructured":"Long MW, Snider DE, Farer LS: U.S. Public Health Service trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis. 1979, 119: 879-894.","journal-title":"Am Rev Respir Dis"},{"key":"197_CR38","first-page":"404","volume":"21","author":"G Buniva","year":"1983","unstructured":"Buniva G, Pagani V, Carozzi A: Bioavailability of rifampicin capsules. Int J Clin Pharmacol Ther Toxicol. 1983, 21: 404-409.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"197_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0962-8479(92)90077-W","volume":"73","author":"SL Chan","year":"1992","unstructured":"Chan SL, Yew WW, Ma WK, Girling DJ, Aber VR, Felmingham D, Allen BW, Mitchison DA: The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuberc Lung Dis. 1992, 73: 33-38. 10.1016\/0962-8479(92)90077-W.","journal-title":"Tuberc Lung Dis"},{"key":"197_CR40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1164\/rccm.200411-1557OC","volume":"172","author":"FA Sirgel","year":"2005","unstructured":"Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rustomjee R, Levin J, Roscigno G, Norman J, McIlleron H, Mitchison DA: The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med. 2005, 172: 128-135. 10.1164\/rccm.200411-1557OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"197_CR41","first-page":"678","volume-title":"Red Book: 2006 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2006","unstructured":"American Academy of Pediatrics: Tuberculosis. Red Book: 2006 Report of the Committee on Infectious Diseases. Edited by: Pickering LK, Baker CJ, Long SS, McMilan JA. 2006, Elk Grove Village, IL: American Academy of Pediatrics, 678-704. 27","edition":"27"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-7-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1741-7015-7-19\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-7-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T22:18:55Z","timestamp":1684966735000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-7-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,22]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["197"],"URL":"https:\/\/doi.org\/10.1186\/1741-7015-7-19","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,22]]},"article-number":"19"}}